Docstoc

prescription_drugs_global_strategic_business

Document Sample
prescription_drugs_global_strategic_business Powered By Docstoc
					Brochure
More information from http://www.researchandmarkets.com/reports/1056053/




Prescription Drugs - Global Strategic Business Report

Description:    This report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following
                therapeutic class – Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump
                Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-
                Epileptics, Autoimmune Agents, and Others. The report provides separate comprehensive analytics
                for the US Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts
                are provided for each region for the period 2006 through 2015. A five-year historic analysis is also
                provided for these markets. The report profiles 292 companies including many key and niche
                players worldwide such as Abbott Laboratories, Allergan, Inc., Amgen, Inc., AstraZeneca, Bayer
                AG, Bristol-Myers Squibb, Boehringer Ingelheim Group, Dr. Reddys Laboratories Ltd., Eli Lilly and
                Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc, Johnson & Johnson,
                Inc., Merck & Co. Inc., Merck Serono International S.A., Mylan, Inc., Novartis AG, Pfizer, Inc.,
                Ranbaxy Laboratories Limited, Sanofi-Aventis SA, Sanofi Pasteur, Takeda Pharmaceutical Company
                Limited, Teva Pharmaceutical Industries Ltd., Watson Pharmaceuticals, Inc., and Wyeth. Market
                data and analytics are derived from primary and secondary research. Company profiles are mostly
                extracted from URL research and reported select online sources.


                Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is
                between 3-5 business days, as each hard copy is custom printed for the organization ordering it.
                Electronic versions require 24-48 hours as each copy is customized to the client with digital controls
                and custom watermarks.

                For information on site licence pricing please click on Enquire before buying



Contents:       I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

                Study Reliability and Reporting Limitations I-1
                Disclaimers I-2
                Data Interpretation & Reporting Level I-2
                Quantitative Techniques & Analytics I-3
                Product Definition and Scope of Study I-3

                II. Executive Summary

                1. INDUSTRY OVERVIEW & OUTLOOK II-1
                Pharma Industry Hit by Economic Downturn II-1
                Table 1: Worldwide Prescription Drugs Sales: 2006-2015
                (includes corresponding Graph/Chart) II-1
                The Regional Impact II-1
                Emerging Markets to Drive Growth II-2
                Biotechnology II-2
                Biotech Bankruptcies Rife in the Current Economic Downturn II-3
                Economic Downturn Takes Toll on R&D II-3
                Outsourcing - A Mixed Bag II-4
                Generics - The Bright Spot II-6
                Table 2: Increasing Share of Generics in the Global
                Pharmaceutical Market: 1995-2005 (In %) (includes
                corresponding Graph/Chart) II-6

                Table 3: Generics Share in Select Markets Worldwide - United
                States, Germany, UK, Spain, Japan, Italy, France, Finland,
                Denmark, The Netherlands, Norway, and Ireland (includes
                corresponding Graph/Chart) II-7
                Patent Expiries of Major Drugs: 2009-2012 II-8
Patient Spending II-8
Operational Restructuring II-9
Rising R&D Costs Call for Improved Efficiency II-9
Concerns Over Drug Safety and Side Effects Impede Sales II-9
Policy Issues Threaten Innovation II-10
Regulatory Glitches and High Costs Hinder Biogeneric Growth II-10
Opportunities Outside Drug Development II-11
Going Forward in Forward Integration II-11
Forward Integration into Diagnostics II-11
Opportunities in Healthcare II-11
Down the Distribution Chain II-12

2. LEADING PHARMA COMPANIES AND DRUGS WORLDWIDE II-13
Pfizer Reigns Supreme II-13
Table 4: Leading Global Pharmaceutical Companies Worldwide by
Sales (2008, 2007, and 2006) - Pfizer, GlaxoSmithKline,
Novartis, Sanofi-Aventis, AstraZeneca, Roche, Johnson &
Johnson, Merck & Co., Abbott and Eli Lilly - in US$ Billion
(includes corresponding Graph/Chart) II-13
Leading Prescription Drugs Worldwide - Lipitor Leads the Way II-14
Table 5: Leading Prescription Drugs Worldwide by Sales (2008,
2007, and 2006)- Lipitor, Plavix, Nexium, Seretide, Enbrel,
Seroquel, Zyprexa, Remicade, Singulair and Levonox in US$
Billion (includes corresponding Graph/Chart) II-14
Oncology Tops Therapeutic Classes II-14
Table 6: Leading Therapeutic Classes Worldwide by Sales
(2008, 2007, and 2006)- Oncologics, Lipid Regulators,
Respiratory Agents, Proton Pump Inhibitors, Antidiabetics,
Antipsychotics, Antidepressants, Angiotensin II Antagonists,
Anti-Epileptics, Autoimmune Agents and Others in US$ Billion
(includes corresponding Graph/Chart) II-15

3. THERAPEUTIC DRUG CLASSES II-16
Cholesterol Reducers II-16
Statins Lead the Way II-16
Emerging Leaders II-16
Table 7: Leading Cholesterol Reducing Drugs Worldwide: Sales
for the years 2004 through 2008 for Lipitor, Crestor and
Vytorin (in US$ Billion) (includes corresponding
Graph/Chart) II-16
Lack of Product Differentiation Mars Prospects II-17
Zocor - The First Statin to Switch to OTC II-17
Patent Expiries of Leading Cholesterol Reducers: 2009 and
Beyond II-17
Oncologics II-17
Oncologics/ Cancer Drugs - Largest Therapeutic Class II-17
High Unmet Needs to Drive Growth II-17
Biologics to Reign Supreme II-18
Leading Drugs II-18
Leading Players II-18
Novel Therapies II-18
Respiratory Drugs II-19
Leading Brands and Players II-19
Table 8: Leading Asthma Drugs Worldwide - Value Sales for
the Years 2004-2008 for Seretide, Singulair, Symbicort and
Pulmicort (in US$ Billion) (includes corresponding
Graph/Chart) II-19

Table 9: Select COPD and Allergic Rhinitis Drugs Worldwide:
Value Sales for the Years 2006-2008 for Spiriva, Nasonex
and Zyrtec (In US$ Billion) (includes corresponding
Graph/Chart) II-20
Patent Expiries of Leading Respiratory Drugs: 2008 and Beyond II-20
Antipsychotics II-20
Leading Schizophrenia Drugs II-21
Side Effects of Antipsychotics - A Major Issue II-21
Patent Expiries II-21
Patent Expiries of Leading Anti-Psychotic Drugs II-22
Zyprexa Continues to Lose Market Share II-22
Risperdal Sales to Plunge, Following its Patent Expiry II-22
Generics - Yet to Make a Mark in Antipsychotics II-22
Increasing Use of Antipsychotics in Children Raises Concerns II-22
Proton Pump Inhibitors II-23
Patent Expiries of Leading Proton Pump Inhibitors: 2008 and
Beyond II-24
Table 10: Leading Proton Pump Inhibitors Worldwide - Value
Sales for the Years 2004 through 2006 (US$ Billion) - Nexium,
Prevacid/Takepron, Protronix/Pantazol and AcipHex/Pariet
(includes corresponding Graph/Chart) II-24
Antidepressants II-24
Patent Expiries of Leading Antidepressant Drugs Worldwide:
2005-2015 II-25
Erythropoietins II-25
Competitive Landscape in the Global Erythropoietin Market II-26
Leading Erythropoietin Drugs II-26
Table 11: Leading Erythropoietin Drugs Worldwide - Annual
Revenues for the Years 2004 through 2007 in US$ Billion for
Aranesp, Procrit/Eprex, Epogen and NeoRecormon (includes
corresponding Graph/Chart) II-26
New and Pipeline Products II-27
Biogenerics Pose Imminent Threat II-27
Anti-Arthritics II-27
Table 12: Leading Anti-arthritic Drugs Worldwide - Value
Sales for Years 2006 through 2008 in US$ Billion - Enbrel,
Remicade, Rituxan and Humira (includes corresponding
Graph/Chart) II-28
Anti-Epileptics II-28
Disease Statistics II-29
Available Drugs II-29
Generics to Take the Lead in Anti-Epileptic Market II-29
Table 13: Leading Anti-Epileptic Drugs Worldwide: Value
Sales for years 2005 through 2007 in US$ Billion for
Topamax, Lamictal, Depakote and Keppra (includes
corresponding Graph/Chart) II-30
Patent Expiries of Leading Anti-Epileptic Drugs II-30
New Launches II-30
Pipeline Drugs Bode Brighter Prospects II-30
Pipeline Drugs in Antiepileptics II-31
Calcium Channel Blockers II-31
Antidiabetics II-31
Table 14: Leading Anti-diabetic Drug Sales Worldwide: Value
Sales for Years 2005 through 2008 in US$ Billion for Actos,
Lantus, Avandia Franchise, Januivia and Byetta (includes
corresponding Graph/Chart) II-32

4. MARKET DYNAMICS II-33
Pharma M&A Activity in 2008 II-33
Aggressive M&A Deals by Japanese Companies II-34
Patent Expiries II-34
Patent Expiries for 2008 and 2007 II-35
New Product Approvals II-35
Table 15: New Drugs Approval from 2003-2008 (includes
corresponding Graph/Chart) II-36

Table 16: Biologics Approvals from 2003-2008 (includes
corresponding Graph/Chart) II-36
Table 17: Development of New Molecular Entities (Biological
and Chemical) by Various Region/Country: Percentage Share
Breakdown for the Periods 1998-2002 & 2003-2007 (includes
corresponding Graph/Chart) II-37

Table 18: Number of Compounds Under Development by
Country/Region: Percentage Breakdown for the year 2007
(includes corresponding Graph/Chart) II-37
New Molecular Entities (NMEs) Approved by FDA in 2008 II-38
New Biological Entities Approved by FDA in 2008 II-38
Research and Development II-39
Table 19: R&D Investments by Pharmaceutical Sector in US and
Europe: 2004-2007 (includes corresponding Graph/Chart) II-39
Cost Pressures II-39
R&D Productivity Slides Despite Increasing Investments II-39
Aging Population Drives Demand II-40
Table 20: World Demographic Trends: People Over 65 as a
Percentage of Total Population by Geographic Region- US,
Canada, Japan, Europe, Asia-Pacific, and Latin America for
years 2000, 2008, 2010, and 2020 (includes corresponding
Graph/Chart) II-40

5. PRESCRIPTION PHARMACEUTICALS - AN OVERVIEW II-41
Biologics II-41
Evolution Of The Global Pharmaceutical Industry II-42
Drug Development Process - FDA Perspective II-43
Stages of Drug Development Process II-43
Drug Discovery II-43
Pre-Clinical Testing II-43
Clinical Trials II-43
Phase I Clinical Trial II-44
Phase II Clinical Trial II-44
Phase III Clinical Trial II-44
New Drug Application II-44
FDA Review II-44
Phase IV Clinical Trials II-44
FDA’s Drug Safety Review - The Global Standard II-44

6. SELECT THERAPEUTIC CLASSES II-46
Anti-arthritics II-46
COX-2 Inhibitors II-46
Antipsychotic Drugs II-46
Anti-Ulcerants II-47
Codeine & Combinations II-47
Combination Drugs II-48
Anti-Depressants II-48
Selective Serotonin Reuptake Inhibitors (SSRIs) II-48
Serotonin Noradrenaline Re-Uptake Inhibitors (SNRIs) II-49
Serotonin Modulators (5-HT2 blockers) II-49
Dopamine-norepinephrine Reuptake Inhibitors II-49
Monoamine Oxidase Inhibitors (MAOIs) II-50
Erythropoietin II-50
Proton Pump Inhibitors II-50
Seizure Disorder Drugs II-51
Antihistamines II-52
Calcium Channel Blockers II-53
Cholesterol Reducers II-54

7. MARKETING AND PROMOTIONS II-55
Table 21: Promotional Spending by Major Pharma Companies (2006
and 2007) in US$ Million - Pfizer, GlaxoSmithKline, Merck,
AstraZeneca, Sanofi-Aventis, Novartis, Eli Lilly,
Schering-Plough, Johnson & Johnson, and Bristol Myers Squibb
(includes corresponding Graph/Chart) II-55

Table 22: Promotional Spending through Professional Detailing
by Major Pharma Companies (2006 and 2007) in US$ Million -
Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Novartis,
Sanofi-Aventis, Eli Lilly, Johnson & Johnson, Schering-Plough
and Wyeth (includes corresponding Graph/Chart) II-56

Table 23: Direct-To-Consumer Promotional Spending By Major
Pharma Companies (2006 and 2007) in US$ Million - Pfizer,
GlaxoSmithKline, Merck, Bristol Myers Squibb, Sepracor,
AstraZeneca, Schering-Plough, Sanofi-Aventis, Boehringer
Ingelheim and Eli Lilly (includes corresponding Graph/Chart) II-56

Table 24: E-Promotional Spending by Major Pharma Companies
(2006 and 2007) in US$ Million - Merck, GlaxoSmithKline,
Johnson & Johnson, Pfizer, Shire, Eli Lilly, Schering-Plough,
AstraZeneca and Sanofi- Aventis (includes corresponding
Graph/Chart) II-57

8. RECENT INDUSTRY ACTIVITY II-58
Merck & Co. and Schering-Plough to Merge II-58
Pfizer to Acquire Wyeth II-58
CSL and Talecris Biotherapeutics to Withdraw Merger Agreement II-58
AstraZeneca Partners with Merck to Analyze a New Combination
of Anticancer Regimen II-58
Sun Pharmaceutical Acquires Chattem II-59
Novartis Acquires 25% Stake in Alcon II-59
Takeda Acquires Millenium Pharmaceuticals II-59
Teva Acquires Barr II-60
Invitrogen and Applied Biosystems Merge II-60
Eli Lilly Takes Over ImClone Systems II-60
Daiichi- Sankyo Acquires Controlling Stake in Ranbaxy II-60
Fresenius Acquires APP Pharmaceuticals II-61
TPG Acquires 50% Stake in SIA International II-61
GSK Acquires Sirtris II-61
Shire Aquires Controlling Interest in Jerini II-61
Boehringer Ingelheim to Purchase Actimis Pharmaceuticals II-61
Sanofi Pasteur Acquires Acambis II-62
Sanofi-Aventis Acquires Symbion II-62
Nordic and Avista Acquires ConvaTec II-62
King Pharmaceuticals Acquires Alpharma II-62
Shionogi Acquires Sciele II-63
Ranbaxy Inks Indian Marketing License for GLIADEL® with BioPro II-63
Tibotec Gains EC Approval for PREZISTA®’s Extended Indication II-63
GSK and Neptunus to Set up Joint Venture for Developing Flu
Vaccines II-64
AstraZeneca Obtains TRO for Generic Pulmicort Respules II-64
Solvay Pharmaceuticals Enters Into a License Deal with Depomed II-64
AstraZeneca Enters into an Agreement with Par Pharmaceutical II-65
BioReliance and Provecs Enter into Agreement II-65
Cornerstone BioPharma and Critical Therapeutics Merge to Form
Cornerstone Therapeutics II-65
GSK to Acquire Genelabs II-66
Lpath and Merck Serono Forge Partnership II-66
Allergan and Spectrum Ink Collaboration Deal for Bladder
Cancer Drug II-66
EMD Signs Licensing and Collaboration Deal with
Theratechnologies II-67
Medimetriks Receives License for Prescription Brands from
Perrigo II-67
Forest Partners with Phenomix for Developing Diabetic Drug II-68
GSK Biologicals and AFFiRiS Sign Collaboration Agreement II-68
Sanofi-Aventis Strengthens R&D Operations in the Chinese Market II-68
UCB and Pfizer Establish Cyclofluidic II-69
Valeant Pharmaceuticals Completes Coria Laboratories Acquisition II-69
MedImmune Inks Agreement with Omninvest over Reverse Genetic
Technology II-70
Avidas Secures North American Rights of Crown’s Dermatology
Products II-70
Lilly Acquires Two Compounds for Early-Stage Tuberculosis
Drug Pipeline II-71
Eli Lilly and Deciphera Enter into Collaboration and
Licensing Deal II-71
Roche, GlycArt and Genentech Sign Collaboration Agreement II-72
Cardinal Health Plans to Spin-Off Medical and Clinical
Products Businesses II-72
Sanofi Pasteur Holding Acquires Acambis II-72
Eisai Plans NDA Submission for Insomnia Drug II-73
GlaxoSmithKline Enter into Strategic Alliance with Cellzome II-73
Ablynx and Merck Serono Sign Nanobodies® Agreement II-74
GlaxoSmithKline and Valeant Enter into Collaborative Agreement II-74
Noven Enters Supply and License Agreements with P&G
Pharmaceuticals II-75
Eli Lilly Acquires SGX Pharmaceuticals II-75
SymBio Pharmaceuticals Enters into a License Agreement with
Eisai II-75
Roche Sells Four Pharmaceutical Products to Meda AB II-76
AstraZeneca Joins Hands with Abbott for Co-Promotion of Crestor II-76
Gilead Sciences Inks Atripla®, HIV Drug Distribution Deal
with Merck II-77
Eisai China Enters into Licensing Deal with Health Vision II-77
GSK and Harvard Stem Cell Institute Team Up for Drug Discovery II-78
Teva Acquires Bentley Pharmaceuticals II-78
Roche to Acquire ARIUS Research II-78
GlaxoSmithKline and Actelion Collaborate II-79
GSK Enters into Product Disinvestment Agreement with Aspen II-79
Lupin Forges Marketing Alliance with ASCEND for Suprax® Tablets II-80
Merck Serono Inks Multiple Sclerosis Drug-Development Deal
with Bionomics II-80
European Commission Approves Kuvan® of Merck Serono II-81
GSK Collaborates with Mpex for Developing Anti-Bacterial Drugs II-81
Eli Lilly Announces Development & Licensing Agreement with
TransPharma II-81
Mylan Obtains Exclusive Marketing Rights for Glatiramer from
NATCO II-82
Sepracor Acquires Oryx Pharmaceuticals II-82
Mylan Takes Over Merck’s Outstanding Generics Operations II-83
Gilead Acquires Cicletanine Business from Navitas II-83
King Pharmaceuticals to License Third Opioid Analgesic Product II-84
BioPhausia Acquires Prescription Pharmaceutical Offerings
from AstraZeneca II-84
Ranbaxy Enters into Strategic Product Development Agreement
with Merck II-84
EUSA Pharma Acquires Cytogen Corporation II-85
Dr. Reddy’s Announces Two Major Acquisitions II-85
EUSA Divests Stake in Antibody Research and Oncology Product
to IDD II-85
Sanofi Pasteur Delivers H5N1 Bulk Vaccine Antigen to HHS II-86
Ranbaxy Inks Strategic Business Alliance with Orchid II-86
Pfizer Settles Patent Litigation for Lipitor with Ranbaxy II-87
GSK Enters into Collaboration with Regulus Therapeutics II-87
Janssen to Launch J&J Group’s New Drugs in Japan II-88
Roche Alliance Partner Obtains Approval for Actemra in Japan II-88
Abbott Receives Japanese Approval for Rheumatoid Arthritis
Drug, HUMIRA® II-88
Dr. Reddy’s Completes Acquisition of Jet Generici Srl II-89
Eli Lilly, Transition Therapeutics Announce Licensing and
Partnership Agreement II-89
Dr. Reddy’s and 7TM Sign Drug Discovery Agreement for
Selected Drug Targets II-89
Endo Pharmaceuticals Obtains US Rights for Novartis’
Voltaren® Gel II-90
Pfizer to Take Over Serenex II-90
Sanofi-aventis, Amyris, iOWH Sign Semisynthetic Artemisinin
Development Deal II-91
AstraZeneca Files sNDA for Depressive Disorder Drug, Seroquel
XR™ II-91
Forest, Mylan Amend Bystolic Agreement II-92
Fujifilm to Acquire Stake in Toyama Chemicals II-92
Graceway Takes Over Estrasorb II-92
Ranbaxy Announces De-Merger of New-Drug Discovery Research Unit II-93
AstraZeneca Inks Deal with Nomura Phase4 Ventures to Form
Albireo II-93
Cellegy to Merge with Adamis Pharmaceuticals II-93
Mylan Reaches Accord with Novartis for Femara®’s Generic Product II-93
Dyax Signs Licensing and Development Agreements with Sanofi-
aventis II-94
AstraZeneca Files for EU Approval of Seroquel XR™ II-94
MedImmune Files Biologics License Application for motavizumab
to FDA II-94
Farmavita, Belupo Sign Contract for Strategic Merger II-94
Pfizer Japan Secures Production and Marketing Approval for
Champix® II-95
Eisai Enters into License Agreement with Abbott II-95
Eisai Takes Over MGI Pharma II-96
KV Pharmaceutical to Acquire Rights for Gestiva™ from Hologic II-96
Forest and Novexel Enter into Licensing Agreement II-96
Dr. Reddy’s Enters Settlement Agreement with Novartis for
Exelon® II-97
Taisho and Pfizer Sign Agreement for TS-032 II-97
Crucell Enters into Agreement with Sanofi Pasteur II-97
EMEA Approves Second Biogeneric EPO, Retacrit II-98
Endo Pharmaceuticals Licenses AZ-003 from Alexza II-98
Schering-Plough and Centocor Modify Existing Distribution
Agreement II-98
GSK and Santaris Pharma Collaborate in RNA Antagonists Research II-99
GSK Acquires Reliant Pharmaceuticals II-99
Eisai and Minophagen Ink In-Licensing Agreement for Liver
Disease/ Allergic Disease Agents II-100
Bristol-Myers, Gilead Extend Agreement to Commercialize
ATRIPLA® in Europe II-100
GSK and OncoMed Team Up for Antibody Therapeutics for Cancer
Stem Cell Research II-101
GSK Allies with Galapagos for Antiviral and Antibacterial
Development II-101
Eisai and BioArctic Ink Licensing Deal for BAN2401 II-102
Biogen and Neurimmune Join Hands to Develop Drugs for
Alzheimers Disease II-102
Sanofi-aventis Institutes GDC, Pharmaceutical Development
Center in India II-103
AstraZeneca Obtains Pediatric Exclusivity for ARIMIDEX® from FDA II-103
Covance to Build High-Tech Drug Development Facility II-103
Schering-Plough Takes Over Organon BioSciences II-104
Takeda Launches Takeda San Francisco for Therapeutic Antibody
Research II-104
GSK to Disinvest Lotronex® II-104
Gilead and LGLS Enter Global License Deal for Fibrotic
Diseases Therapy II-105
Watson Acquires Andrx II-105
EPFL and Merck Serono Enter into Agreement II-106
Acura and King R&D Sign Licensing Agreement for Opioid
Analgesic Products II-106
Eli Lilly Inks License Agreement with Glenmark Pharmaceuticals II-107
Wockhardt Takes Over Morton Grove Pharmaceuticals II-107
GSK Enters into Collaboration with Tolerx for Development of
Novel Therapies II-108
Chugai Pharmaceuticals Obtains Approval for Tarceva in Japan II-108
Eli Lilly Announces Strategic Alliance with MacroGenics II-108
BMS, ImClone, Merck Serono Sign Erbitux® Agreement II-109
Wockhardt to Market Gnosis’ SAMe in India II-110
Alpharma Grants US License for Ketoprofen in Transfersome®
Gel to IDEA II-110
Forest and Daiichi Sankyo Sign Contract to Co-Promote AZOR™ II-110
Synta and GSK Sign Oncology Molecule Development Collaboration II-110
Cyclacel to Take Over ALIGN Pharmaceuticals and ALIGN Holdings II-111
GSK Inks Antiviral and Antibacterial Drug Development Deal
with Anacor II-111
AMRI Enters into Research Collaboration with Cystic Fibrosis
Foundation II-112
Mylan Takes over Merck Generics II-112
Kissei and Eisai Ink Licensing Deal for Glufast® Tablets II-112
AMRI Inaugurates New Research Unit in Hyderabad II-113
Eisai Inks Co-Promotion Deal with Salix for COLAZAL® Capsules II-113
Kowa and Teva to Establish Joint Venture Generic Drug Firm in
Japan II-113
Nisshin Seifun Pulls Out of Joint Venture Nisshin Kyorin
Pharmaceutical II-114
Chugai and Teijin Sign Agreement for Co-Development of Anti-
Diabetic Drug II-114
MedImmune Inks Licensing Agreement with Novartis over Reverse
Genetic Technology II-114
EUSA Acquires Assets of Innocoll II-115
Noven Enters Supply and License Agreements with P&G
Pharmaceuticals II-115
Parion and Gilead Ink Deal to Develop Drug Candidates for
Pulmonary Disease II-116
Noven Pharmaceuticals Acquires JDS Pharmaceuticals II-116
HHS Places an Order with GSK for Bulk H5N1 Antigen II-117
Synthon Completes Laboratorios Rider Acquisition II-117
Targacept Forges Partnership with GSK II-118
Dong Wha Signs Alliance with P&G Pharma to Develop Treatment
Molecules for Osteoporosis II-118
Barr and Gedeon Richter Sign Pact over Generic Version of
LAMISIL® II-118
Santarus and Victory Pharma Enter Into Co-Promotion Agreement II-119
AMRI Enters into Collaboration for Research with Achaogen II-119
SCI Collaborates with High Q Foundation for Research on
Huntington’s Disease II-120
MonoSol Rx Signs License Agreement with Strativa Pharmaceuticals II-120
Eli Lilly to Launch Public-Private Partnership for Drug
Research in Tuberculosis II-120
Merck Serono and Bristol-Myers Squibb Ink Latin American
Distribution Deal II-121
Strides Arcolab to Take Over Bio-Fermentation Facility in Italy II-121
Amgen to Take Over Alantos Pharmaceuticals II-121
GlaxoSmithKline Establishes R&D Center in China II-122
Wockhardt Acquires Negma Laboratories II-122
Eisai Inks Exclusive Agreement with Solstice over NeuroBloc® II-122
Ranbaxy to Acquire Be-Tabs Pharmaceuticals II-123
Pfizer Obtains Health Canada Approval for LIPITOR in Reducing
Myocardial Infarction II-123
GSK Allies with Wellcome to Develop Antibacterials for
Hospital-Contracted Infections II-124
Bristol-Myers and Pfizer Ink Development and
Commercialization Agreements II-124
Cytos Biotechnology Grants Novartis with Global License for
NicQb II-125
Swiss Federal Register Adds ACOMPLIA® to Reimbursement List II-125
Wockhardt to Introduce Syrio Pharma’s B-Lift Product Range in
India II-126
Eisai Acquires Morphotex II-126
Ranbaxy Obtains Approval for RAN™ Cefprozil Formulations in
Canada II-126
Roche Partners with Transgene to Focus on Therapeutic Vaccine
Program II-127
Cardinal Health Divests Pharmaceutical Technologies and
Services Segment to Blackstone Group II-127
Roche to Acquire BioVeris Corporation II-128
Eli Lilly Acquires Hypnion II-128
Roche Takes Over THP, Broadens Antibody Research Facility II-128
Oxford BioMedica Enters into Development Deal with Sanofi-
Aventis for TroVax® II-129
Iroko Pharmaceuticals Acquires Rights to Indocin® and
Aldomet® Products II-129
Asahi Kasei Inks Licensing Agreement with Eisai Korea over
Vasodilator Eril® II-129
Merck Obtains EU Approval for JANUVIA™ Type 2 Diabetes Drug II-130
Wockhardt Obtains FDA Approval for a Painkiller in the US II-130
Ortho-McNeil Obtains Pediatric Extension for LEVAQUIN® II-131
GlaxoSmithKline Obtains FDA Approval for Tykerb® II-131
Terapia Ranbaxy Secures Marketing Approvals for 20 New Products II-131
Shionogi to Develop and Market BioCrysts peramivir in Japan II-131
Abbott and Eisai Amend Co-Promotion Agreement over HUMIRA® in
Korea and Taiwan II-132
Salix Acquires US Rights to Merck’s Two Oral Suspension Products II-132
Takeda Expands Collaboration with XOMA in Potential
Therapeutic Antibody Programs II-133
GSK Commences Phase III Clinical Trials of Tykerb®, a Post-
Operative Lapatinib II-133
Roche Grants Glaxo with Exclusive Licensing Rights to its ‘
Orlistat’ Drug II-134
GSK and HGS Commence Phase III Trials of LymphoStat-B® in SLE II-134
GSK and Fabre-Kramer Ink Global Deal for Gepirone ER II-134
Ranbaxy Signs Agreement with Zenotech for Biosimilars’ Global
Launch II-135
Ranbaxy Inks Long-Term R&D Deal with GSK II-135
Amgen Inks Three-year Aranesp Supply Agreement with Fresenius II-136
AstraZeneca to Take Over Arrow Therapeutics II-136
Eli Lilly Acquires ICOS Corporation II-136
Pfizer Plans to Takeover BioRexis II-136
Solvay Inks Licensing Deal with Jazz Pharmaceuticals for LUVOX® II-137
Eisai’s ‘Pariet®, 10mg Tablets’ Receive Clearance for New
Indication in Japan II-137
Eisai Receives EC Approval for Inovelon® II-137
Pfizer Receives Marketing Authorization for Sutent® in
European Union II-137
GlaxoSmithKline Obtains Approval to Market Wellbutrin XR® in
the Netherlands II-138
Forest Laboratories Acquires US Biopharmaceutical Company,
Cerexa II-138
Mylan Laboratories Acquires 51.5% in Matrix II-139
DUSA Enters into an Agreement with Daewoong Pharmaceutical II-139
Penwest and Endo Amend Existing Contract on Opana® ER
Collaboration II-139
Eli Lilly Licenses Glucokinase Activator Program from OSI
Pharmaceuticals II-140
Graceway Pharmaceuticals Acquires 3M Pharmaceuticals Business II-140
Ranbaxy Obtains FDA Approval for Atenolol Tablets II-140
Gilead Sciences Acquires Myogen II-141
Gilead Sciences Acquires Raylo Chemicals II-141

9. FDA APPROVALS FOR 2009, 2008 AND 2007 II-142

10. A REVIEW OF SELECT PRODUCT INTRODUCTIONS IN THE PHARMA INDUSTRY II-144
Amgen Receives Approval for Nplate(R) II-144
Takeda Wins FDA Marketing Approval for ULORIC II-144
Novartis and MMV Launch Coartem® Dispersible II-144
Ipsen and Medicis Receives FDA Approval for Dysport II-144
Centocor Receives FDA Approval for Simponi II-145
Wyeth Receives FDA Approval for PRISTIQ™ II-145
GSK Receives FDA Approval for Promacta® II-145
Cephalon Receives FDA Approval for TREANDA II-145
Adolor Receives FDA Approval For Entereg(R) II-145
Lundbeck Introduces Xenazine* (Tetrabenazine) Tablets II-146
Eisai US Receives FDA Approval for Banzel™ (Rufinamide) II-146
Progenics Receives FDA Approval for RELISTOR II-146
J&J Receives Approval for Anti-HIV Medication ‘Intelence’ II-146
Sandoz Launches Generic Fluoxetine Hydrochloride Capsules in US II-146
Sandoz Introduces Eplerenone Tablets II-147
Wockhardt Introduces Midazolam Injection in the US II-147
Dr. Reddy’s Announces Launch of Generic Version of Imitrex®
Tablets II-147
Arbor Pharmaceuticals Debuts NEOTIC™ for Middle- Ear Infections II-147
Promius Pharma Introduces EpiCeram® Emulsion II-147
Sandoz Unveils Generic Variant of Imitrex® Injection II-148
Dr. Reddy’s Launches Redihaler™ and Combihale™ II-148
Wyeth Launches Antihemophilic Factor, XYNTHA™ II-148
Bayer Schering Releases YAZ® II-148
Mylan Introduces Nisoldipine ER Tablets in US II-149
Ranbaxy Launches Generic Omeprazole in US II-149
Ranbaxy Unveils Generic Equivalent of Amlodipine Tablets II-149
Teva Unveils Generic Equivalent of Lamictal® Tablets II-149
Eisai and Helsinn Healthcare Introduce ALOXI® Injection for
Prevention of PONV II-150
Janssen and Patriot Unveil Authorized Generic Equivalent for
Risperdal® II-150
Watson Releases Generic Equivalent of MARINOL® II-150
Sandoz Introduces Generic Form of Altace® II-151
Abbott Introduces Aluvia® Tablet in South Africa II-151
Dr. Reddy’s Rolls-out Atocor-R II-151
Sandoz Unveils Generic Form of Maxipime® II-151
Tibotec Therapeutics Introduces New 600mg Dosage Strength for
PREZISTA II-152
Ranbaxy Pioneers Launch of New Bio-Generic Recombinant
Osteoporosis Injection II-152
Sandoz Introduces Generic Variant of Antizol® Injection II-152
Sun Pharmaceuticals Introduces Injection of Amifostine II-152
Sandoz Re-Launches Generic Form of Bactocill® Injection II-153
Sandoz Introduces Generic Form of Cipro® Injection II-153
Merck Serono Introduces Cyanokit® in Japanese Market II-153
Ranbaxy Launches INERSAN Tablets in India and Nepal II-153
Sandoz Launches Omnitrope™ Pen 5 with Liquid Cartridge II-153
Endo Pharmaceuticals to Introduce OPANA® ER in Three Dosage
Strengths II-154
Sandoz Releases Generic Form of Camptosar® II-154
Sun Pharmaceuticals Unveils Pantoprazole Sodium DR Tablets II-154
Dr. Reddy’s Introduces Supanac® II-154
Watson Announces Launch of Clarithromycin 500mg Extended-
Release Tablets II-155
GSK Announces FDA approval of Altabax™ II-155
Novartis’ Tekturna HCT® Receives FDA Approval II-155
GSK Receives FDA Approval for Tykerb® II-155
Pfizer Receives FDA Approval for Selzentr II-155
Ortho-McNeil Receives Approval for DORIBAX™ II-155
Merck Receives Approval for Isentress® II-156
BMS Wins FDA Approval for IXEMPRA™ II-156
Novartis’ Tasigna® Receives FDA Approval II-156
Mylan Receives FDA Approval for Bystolic II-156
Roche’s Mircera Secures FDA Approval II-156
Eisai Launches New Dose Formulations of Aricept® Tablets in
Japan II-157
Chugai Launches Tarceva® Tablet in Japan II-157
Sandoz Introduces Generic Version of Elocon® Lotion II-157
Ranbaxy to Introduce Tamsulosin Hydrochloride Capsules in Canada II-157
Watson Unveils Tilia™ Fe II-157
Ranbaxy Obtains Health Canada Approval for Ran®- Lisinopril
Oral Tablets II-158
Sandoz Releases Generic Form of Delestrogen® Injections II-158
Sanofi and UCB Roll Out XYZAL® in US II-158
Sandoz Expands Range of Generic Augmentin® Drugs II-159
Sandoz Releases Generic Variant of Biaxin® for Oral Suspension II-159
Sandoz Introduces Generic Form of Penlac® Topical Solution II-159
Teva Releases Famciclovir Tablets II-159
Ranbaxy Introduces Roliflo OD in India II-159
Sandoz Introduces Generic Form of Toprol Xl® 50Mg Extended
Release Tablet II-160
Dr. Reddy’s Introduces Glimy MP1 and Glimy MP2 II-160
Sandoz Launches Approved Generic Equivalent of Lamisil® II-160
Ranbaxy Introduces Pravastatin Sodium 80mg Tablets in the US II-160
AstraZeneca Announces the Availability of Symbicort® pMDI II-160
Chugai and Maruho Announce the Launch of Oxarol® Lotion II-161
Ajinomoto and Eisai Jointly Launch ‘Actonel® 17.5mg Tablets’ II-161
Sandoz Introduces Approved Generic Form of Lotrel® II-161
Dr. Reddy’s Launches UltravexTM II-162
Wockhardt Unveils Zolpidem Tablets in the US II-162
Dr. Reddy’s Introduces Reditux™ II-162
Dr. Reddy’s Secures Approval for Launching Zolpidem Tartrate
Tablets II-162
Cipla Introduces Virenza Inhalation Capsules in India II-162
Ranbaxy Introduces Osovair in India II-163
GlaxoSmithKline Introduces Coreg CR™ II-163
Chugai Announces the Launch of Antiviral Agent, Copegus® Tablet II-163
Ranbaxy Unveils Generic Atorvastatin in Denmark II-163
Barr Unveils Generic ‘PROSCAR®’ Tablets II-164
Ranbaxy Introduces Niftran 100mg Capsules and Eligard 22.5mg
and 45mg II-164
Barr Releases METAGLIP™ Tablets II-164
SkinMedica Rolls Out Single-Dosage NeoBenz® Micro SD for
Treating Acne II-165
Teva Rolls Out Generic Equivalent of Wellbutrin XI® Tablets II-165
Takeda Launches Takepron ® I.V for Injection 30mg II-165
Takeda Launches duetact™ Combination Drug in USA II-166
Teijin Pharma Launches Bonalon® Tablet for Treating Osteoporosis II-166

11. FOCUS ON SELECT GLOBAL PLAYERS II-167
Abbott Laboratories (USA) II-167
Allergan, Inc. (USA) II-167
Amgen, Inc. (USA) II-168
AstraZeneca (UK) II-169
Bayer AG (Germany) II-170
Bristol-Myers Squibb (USA) II-170
Boehringer Ingelheim Group (Germany) II-170
Dr. Reddys Laboratories Ltd. (India) II-171
Eli Lilly and Company (USA) II-172
F. Hoffmann-La Roche Ltd. (Switzerland) II-172
Genentech, Inc. (USA) II-173
GlaxoSmithKline Plc (UK) II-173
Johnson & Johnson, Inc. (USA) II-174
Merck & Co. Inc. (USA) II-174
Merck Serono International S.A. (Switzerland) II-175
Mylan, Inc. (USA) II-175
Novartis AG (Switzerland) II-176
Pfizer, Inc. (USA) II-177
Ranbaxy Laboratories Limited (India) II-177
Sanofi-Aventis SA (France) II-178
Sanofi Pasteur (France) II-178
Takeda Pharmaceutical Company Limited (Japan) II-179
Teva Pharmaceutical Industries Ltd. (Israel) II-179
Watson Pharmaceuticals, Inc. (USA) II-180
Wyeth (USA) II-181

12. GLOBAL MARKET PERSPECTIVE II-182
Table 25: World Recent Past, Current & Future Analysis for
Prescription Drugs Market by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, Latin America and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Billion for Years 2006 through 2015 (includes corresponding
Graph/Chart) II-182

Table 26: World Historic Review for Prescription Drugs Market
by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Billion for
Years 2001 through 2005 (includes corresponding Graph/Chart) II-183

Table 27: World 15-year Perspective for Prescription Drugs
Market by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin
America and Rest of World Markets for Years 2003, 2009 & 2015
(includes corresponding Graph/Chart) II-184

Table 28: World Recent Past, Current & Future Analysis for
Prescription Drugs Market by Therapeutic Class - Oncologics,
Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors,
Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II
Antagonists, Anti-Epileptics, Autoimmune Agents and Others
Markets Independently Analyzed with Annual Sales in US$
Billion for Years 2006 through 2015 (includes corresponding
Graph/Chart) II-185

Table 29: World Historic Review for Prescription Drugs Market
by Therapeutic Class - Oncologics, Lipid Regulators,
Respiratory Agents, Proton Pump Inhibitors, Antidiabetics,
Antipsychotics, Antidepressants, Angiotensin II Antagonists,
Anti-Epileptics, Autoimmune Agents and Others Markets
Independently Analyzed with Annual Sales in US$ Billion for
Years 2001 through 2005 (includes corresponding Graph/Chart) II-186

Table 30: World 15-year Perspective for Prescription
Pharmaceuticals Market by Therapeutic Class- Percentage
Breakdown of Dollar Sales for Oncologics, Lipid Regulators,
Respiratory Agents, Proton Pump Inhibitors, Antidiabetics,
Antipsychotics, Antidepressants, Angiotensin II Antagonists,
Anti-Epileptics, Autoimmune Agents and Others Markets for
Years 2003, 2009 & 2015 (includes corresponding Graph/Chart) II-187

III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Generics in the US III-1
Biologics Post Highest Growth III-1
Leading Prescription Drugs in the US III-2
Table 31: Leading Prescription Drugs in the US by Value
Sales (2008) in US$ Billion - Lipitor, Nexium, Plavix,
Advair Diskus, Seroquel, Singulair, Enbrel, Neulasta, Actos
and Epogen (includes corresponding Graph/Chart) III-2
Leading Therapeutic Classes in the US III-2
Table 32: US Leading Therapeutic Classes by Revenue
(2006-2008): Revenues for Antipsychotics, Lipid Regulators,
Proton Pump Inhibitors, Seizure Disorders,
Anti-Depressants, Angiotensin II Antagonists, Anteneo
Monoclonal Antibodies, Erythropoietins, Anti-Arthritics and
Oral Antiplatelets (in US$ Billion) (includes corresponding
Graph/Chart) III-3

Table 33: US Leading Therapeutic Classes by Dispensed
Prescriptions (2006-2008): Percentage Share Breakdown for
Lipid Regulators, Codiene & Combinations, Anti-Depressants,
Ace Inhibitors, Beta Blockers, Proton Pump Inhibitors,
Seizure Disorders, Synthetic Thyroid Hormones, Calcium
Blockers, Benzodiazepines, and Others (includes
corresponding Graph/Chart) III-4
Leading Players III-5
Table 34: Leading Companies in the US Pharmaceutical Market
(2006-2008): Percentage Breakdown of Value Sales for
Pfizer, GlaxoSmithKline, Merck & Co., Johnson & Johnson,
AstraZeneca, Amgen, Novartis, Hoffman-La Roche,
Sanofi-Aventis, Eli Lilly and Others (includes
corresponding Graph/Chart) III-5

Table 35: US Pharmaceutical Market (2006-2008): Percentage
Breakdown of Dispensed Prescriptions for Teva
Pharmaceuticals, Mylan Laboratories, Novartis, Watson
Pharma, Pfizer, Barr Laboratories, Merck & Co.,
Mallinckrodt, Apotex, Qualitest, and Others (includes
corresponding Graph/Chart) III-6
Prescription Drug Spending III-6
Table 36: Healthcare Spending in the US by Sector (2006)
(includes corresponding Graph/Chart) III-7
Increasing Share of Government in Prescription Drug Spending III-8
Table 37: US Prescription Pharmaceutical Industry (2005
and 2006): Percentage Breakdown of Prescription
Pharmaceutical Spending by Source for Private Insurance,
Medicare, Medicaid, Out-of-Pocket and Other Public
Spending (includes corresponding Graph/Chart) III-8
Medicare Part D III-8
Drug Price Regulations in the US III-9
Pharmaceutical Marketing - A High Investment Area in the US III-9
Table 38: Pharmaceutical Promotional Spending in the US by
Type (2006-2008): Professionals-Directed Promotions and
Consumer-Directed Promotions (in US$ Billion) (includes
corresponding Graph/Chart) III-10
Major Distribution Channels III-10
Table 39: Major Prescription Drugs’ Distribution Channels
in the US by Dispensed Prescriptions (2006-2008):
Percentage Share Breakdown for Chain Stores, Independent
Stores, Food Stores, Long-term Care, and Mail Order
(includes corresponding Graph/Chart) III-11

Table 40: Major Prescription Drugs’ Distribution Channels
in the US by Value Sakes (2006-2008): Percentage Breakdown
for Distribution Channel for Chain Stores, Mail Order,
Independent Stores, Clinics, Non-government Hospitals, Food
Stores and Other Channels (includes corresponding
Graph/Chart) III-11
Fewer Product Launches III-12
Generic Penetration and PBMs Moderate Prescription Drug
Price Growth III-12
Co-payment Differentials to Increase Generic Substitution III-12
High Prescription Drug Costs Drive Drug Re- Importation III-12
Direct-to-Consumer Advertising III-12
The 2006 Revision of Package Insert Format III-13
Other Initiatives III-13
Role of PBMs in the Pharmaceutical Supply Chain III-13
Prescription Drug Pricing in US III-14
Role of Mail-Order Pharmacies in Cost Containment III-15
Product Launches III-15
Strategic Corporate Developments III-30
Select Key Players III-63
B.Market Analytics III-71
Table 41: US Recent Past, Current & Future Analysis for
Prescription Drugs Market Analyzed with Annual Sales in US$
Billion for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-71

Table 42: US Historic Review for Prescription Drugs Market
Analyzed with Annual Sales in US$ Billion for Years 2001
through 2005 (includes corresponding Graph/Chart) III-71

Table 43: US Recent Past, Current & Future Analysis for
Prescription Pharmaceuticals by Therapeutic Class -
Antipsychotics, Lipid Regulators, Proton Pump Inhibitors,
Seizure Disorder Drugs, Anti-Depressants, Angiotensin II
Antagonists, Antineo Monoclonal Antibodies, Erythropoietins,
Others, Market Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-72

Table 44: US Historic Review for Prescription
Pharmaceuticals by Therapeutic Class - Antipsychotics, Lipid
Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs,
Anti-Depressants, Angiotensin II Antagonists, Antineo
Monoclonal Antibodies, Erythropoietins, Others, Market
Analyzed with Annual Sales in US$ Billion for Years 2001
through 2005 (includes corresponding Graph/Chart) III-73

Table 45: US 15-Year Perspective for Prescription
Pharmaceuticals by Therapeutic Class - Percentage Breakdown
of Dollar Sales for Antipsychotics, Lipid Regulators, Proton
Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants,
Angiotensin II Antagonists, Antineo Monoclonal Antibodies,
Erythropoietins, and Others for Years 2003, 2009 & 2015
(includes corresponding Graph/Chart) III-74

2. CANADA III-75
A.Market Analysis III-75
Current and Future Analysis III-75
Leading Drugs III-75
Table 46: Leading Prescription Drugs in Canada in Terms of
Number of Dispensed Prescriptions (2006 and 2007) in
Million Scripts: Lipitor, Synthroid, Norvasc, Asaphen,
Pantoloc, Crestor, Altace, Ratio-Salbutamol Hfa,
Novo-Venlafaxine XR and Apo- Furosemide (includes
corresponding Graph/Chart) III-75
Major Therapeutic Classes III-76
Table 47: Leading Therapeutic Classes in Canada in terms of
Dispensed Prescription (2006 and 2007): Percentage
Breakdown of Cardiovascular, Antipsychotics,
Gastrointestinal/Genitourinary, Lipid Regulators, Hormones,
Systemic Anti-infective, Analgesics, Diabetes Therapy,
Diuretics, Neurological Disorders and Others (includes
corresponding Graph/Chart) III-76
Prescription Drugs Spending on the Rise III-77
Private Sector Insurance Continues to Gain Popularity III-77
Canadian Prescription Drugs Market- A Comparison with the US III-77
Generic Sales to Outpace Branded Drugs Sales III-77
Generics Market in Canada III-77
Generics to Offer Potential Cost Savings III-77
New Patented Drugs- Adding Costs but Little Value III-78
Two-level Drug Approval Process in Canada III-78
Policy Differences Affect Generic Substitution Among Provinces III-78
Applied and Other Research Take Major Chunk of R&D
Investments in Canada III-78
Table 48: Investments in Research & Development in Canada
(1998, 2001, 2004 and 2007): Percentage Breakdown by
Research Type- Applied Research, Basic Research and Other
Research Areas (includes corresponding Graph/Chart) III-79
Product Launches III-79
Strategic Corporate Developments III-81
B.Market Analytics III-82
Table 49: Canadian Recent Past, Current & Future Analysis
for Prescription Drugs Market Analyzed with Annual Sales in
US$ Billion for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-82

Table 50: Canadian Historic Review for Prescription Drugs
Market Analyzed with Annual Sales in US$ Billion for Years
2001 through 2005 (includes corresponding Graph/Chart) III-82

3. JAPAN III-83
A.Market Analysis III-83
Current and Future Analysis III-83
Generics Promotion in Japan III-83
Ageing Population - A Prime Target III-83
Competitive Landscape III-84
Table 51: Leading Pharmaceutical Companies in Japan (2008):
Percentage Breakdown of Revenues for Takeda
Pharmaceuticals, Astellas Seiyaku, Dai-ichi Sankyo,
Mitsubishi Tanabe, Chugai Seiyaku, Pfizer, Novartis, Eisai,
GlaxoSmithKline and Otsuka Seiyaku (includes corresponding
Graph/Chart) III-84

Table 52: Leading Prescription Drugs in Japan (2006 and
2007): Value Sales in US$ Million for Blopress, Diovan,
Norvasc, Lipitor, Aricept, Epogin, Takepron, Leuplin,
Micardis and Amlodin (includes corresponding Graph/Chart) III-85
Cancer Drugs to Witness Robust Growth III-85
Biennial Price Reduction to Impact Markets of Key
Therapeutic Classes III-85
Product Launches III-86
Strategic Corporate Developments III-88
Select Key Players III-94
B.Market Analytics III-95
Table 53: Japanese Recent Past, Current & Future Analysis
for Prescription Drugs Market Analyzed with Annual Sales in
US$ Billion for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-95

Table 54: Japanese Historic Review for Prescription Drugs
Market Analyzed with Annual Sales in US$ Billion for Years
2001 through 2005 (includes corresponding Graph/Chart) III-95

4. EUROPE III-96
A.Market Analysis III-96
Current and Future Analysis III-96
Pharmaceutical Spending on the Rise III-96
Mounting Healthcare Bills Boost Generic Drugs Consumption III-96
Biogenerics Foray into Europe III-97
SNRIs Likely to Replace SSRIs III-97
Research and Development III-97
Table 55: European Investments in Pharma Research &
Development: 2005-2007 (includes corresponding Graph/
Chart) III-97
Europe - The Research and Production Hub for Vaccines
Worldwide III-98
Parallel Trade in Europe III-98
New Rules to Offer Respite to Parallel Traders III-98
Manufacturers Seek Greater Control Over Supply Chain III-98
Pharmaceutical Industry Overview In Select Countries III-99
France III-99
Germany III-99
Generics III-99
Exports III-100
Production III-100
Prices III-100
New Molecular Entities III-100
R&D Investments III-100
Parallel trade III-100
Genetically Manufactured Drugs III-101
Table 56: German Genetically Manufactured Pharmaceuticals
(2007): Percentage Breakdown of Sales by Type - Vaccines,
Insulins, Interferons, Monoclonal Antibodies,
Erythropoietin, and Others (includes corresponding
Graph/Chart) III-101
United Kingdom III-101
Spain III-101
Cost Containment Efforts III-102
Increased Promotion for Generics III-102
Re-launch of Reference Price System III-102
Distribution III-102
Italy III-103
Generics Gain Traction III-103
Sweden III-103
Greece III-103
Unique Pricing Model for Drugs III-103
Product Launches III-104
Strategic Corporate Developments III-106
Select Key Players III-123
B.Market Analytics III-128
Table 57: European Recent Past, Current & Future Analysis
for Prescription Drugs Market Analyzed with Annual Sales in
US$ Billion for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-128
Table 58: European Historic Review for Prescription Drugs
Market Analyzed with Annual Sales in US$ Billion for Years
2001 through 2005 (includes corresponding Graph/Chart) III-129

5. ASIA-PACIFIC III-130
A.Market Analysis III-130
Current and Future Analysis III-130
Overview of Pharmaceutical Industries in Select Countries III-130
India III-130
Competitive Advantage III-130
Number of FDA Approved Plants in India Vis-à-Vis Other
Countries III-131
Increasing Disposable Income Driving Consumption of Drugs III-131
Generics to Surge Growth in Exports III-131
Manufacturers Continue to Target Developed Markets III-131
India to Emerge as an Important Pharmaceutical
Manufacturing Center III-132
Threat from Other Asian Countries III-132
India to Emerge as a Major Hub for Biogenerics III-132
Acute Therapy Class Leads the Market III-132
Table 59: Leading Therapeutic Categories in the Indian
Pharmaceutical Industry- Percentage Share Breakdown of
Value Sales for Anti-infectives, Gastrointestinal,
Cardiovascular, Respiratory, Minerals and Vitamins,
Analgesics, Women’s Health, Central Nervous System,
Dermatology, and Others (includes corresponding
Graph/Chart) III-133
Increase in Private Healthcare Services III-133
China III-133
Chinese Pharma Industry Remains Immune to Global Crisis,
for Now III-134
Issues and Trends III-134
Pharmaceutical Firms to Play Pivotal Role in Transforming
Healthcare System III-135
Brand Name Drugs to Exhibit Fastest Growth, While
Generics Continue to Lead III-135
Generics in China III-135
Traditional Medicines - Substantial Share III-136
Table 60: Leading Medicine Types in China (2005):
Percentage share for Allopathic Medicines, Traditional
Chinese Medicines (TCM), and Other Drugs (includes
corresponding Graph/Chart) III-136
Underserved Markets Prompt Government to Foster Development III-137
Domestic EPO Market Booming, Domestic Players Continue
their Domination III-137
Chinese Antipsychotics Market to Witness Substantial Growth III-137
Antidepressant Drugs to Exhibit Robust Sales III-138
Indonesia III-138
Market Features III-138
Government-Enforced Pricing Control Over Essential Drugs III-138
Distribution III-139
Korea III-139
Patent Expiries of Leading Drugs in South Korea: 2008 and
2009 III-139
Malaysia III-140
Foreign Investments on the Rise III-140
Domestic Market III-140
Australia III-141
Pharmaceutical Benefits Scheme III-141
Government’s Industry Development Programs III-142
Outlook III-142
Product Launches III-143
Strategic Corporate Developments III-146
Select Key Players III-153
B.Market Analytics III-155
Table 61: Asia-Pacific Recent Past, Current & Future
Analysis for Prescription Drugs Market Analyzed with Annual
Sales in US$ Billion for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-155

Table 62: Asia-Pacific Historic Review for Prescription
Drugs Market Analyzed with Annual Sales in US$ Billion for
Years 2001 through 2005 (includes corresponding
Graph/Chart) III-155

6. LATIN AMERICA III-156
A.Market Analysis III-156
Current and Future Analysis III-156
Strategic Corporate Developments III-156
B.Market Analytics III-157
Table 63: Latin American Recent Past, Current & Future
Analysis for Prescription Drugs Market Analyzed with Annual
Sales in US$ Billion for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-157

Table 64: Latin American Historic Review for Prescription
Drugs Market Analyzed with Annual Sales in US$ Billion for
Years 2001 through 2005 (includes corresponding
Graph/Chart) III-157

7. REST OF WORLD III-158
A.Market Analysis III-158
Current and Future Analysis III-158
Product Launches III-158
Strategic Corporate Developments III-158
B.Market Analytics III-160
Table 65: Rest of World Recent Past, Current & Future
Analysis for Prescription Drugs Market Analyzed with Annual
Sales in US$ Billion for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-160

Table 66: Rest of World Historic Review for Prescription
Drugs Market Analyzed with Annual Sales in US$ Billion for
Years 2001 through 2005 (includes corresponding
Graph/Chart) III-160

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 292 (including Divisions/Subsidiaries - 360)

Region/Country Players

The United States / 246
Canada / 4
Japan / 27
Europe / 57
France / 4
Germany / 9
The United Kingdom / 11
Italy / 4
Rest of Europe / 29
Asia-Pacific (Excluding Japan) / 22
Latin America / 1
Africa / 3
Ordering:   Order Online - http://www.researchandmarkets.com/reports/1056053/

            Order by Fax - using the form below

            Order by Post - print the order form below and sent to

                         Research and Markets,
                         Guinness Centre,
                         Taylors Lane,
                         Dublin 8,
                         Ireland.
                                                           Page 1 of 2

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-
1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.


               Product Name:           Prescription Drugs - Global Strategic Business Report
               Web Address:            http://www.researchandmarkets.com/reports/1056053/
               Office Code:            OC8HQKKRUTTSW

Product Formats
Please select the product formats and quantity you require:


                                   Quantity
               Electronic -
                                         EURO €3,496.00
               Single User:

               Hard Copy - :             EURO €3,496.00 + Euro €50 Shipping/Handling *


* Shipping/Handling is only charged once per order.



Contact Information
Please enter all the information below in BLOCK CAPITALS


      Title:                  Mr              Mrs           Dr           Miss                 Ms     Prof

      First Name:                                                  Last Name:

      Email Address: *

      Job Title:

      Organisation:

      Address:

      City:

      Postal / Zip Code:

      Country:

      Phone Number:

      Fax Number:

     * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
                                                              Page 2 of 2

Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

          Pay by credit card:                     American Express

                                                  Diners Club

                                                  Master Card

                                                  Visa
                                           Cardholder's Name

                                           Cardholder's Signature

                                           Expiry Date

                                           Card Number

                                           CVV Number

                                           Issue Date
                                           (for Diners Club only)




          Pay by check:                    Please post the check, accompanied by this form, to:

                                           Research and Markets,
                                           Guinness Center,
                                           Taylors Lane,
                                           Dublin 8,
                                           Ireland.


                                           Please transfer funds to:
          Pay by wire transfer:
                                           Account number                   833 130 83
                                           Sort code                        98-53-30
                                           Swift code                       ULSBIE2D
                                           IBAN number                      IE78ULSB98533083313083
                                           Bank Address                 Ulster Bank,
                                                                        27-35 Main Street,
                                                                        Blackrock,
                                                                        Co. Dublin,
                                                                        Ireland.


     If you have a Marketing Code please enter it below:


           Marketing Code:


      Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
     http://www.researchandmarkets.com/info/terms.asp



                                              Please fax this form to:
                                  (646) 607-1907 or (646) 964-6609 - From USA
                          +353 1 481 1716 or +353 1 653 1571 - From Rest of World

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:7
posted:10/12/2011
language:English
pages:21